Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.45 |
| ▸ | GABRD | O14764 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.45 |
| ▸ | GABRE | P78334 | 1/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.45 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.45 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.45 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13790503 | 0.75 | ALDH1A1 (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9245844 | 0.74 | TUBB4A (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9626870 | 0.74 | TUBB4A (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9659250 | 0.74 | TUBB4A (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL26080869 | 0.70 | ALDH1A1 (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28541685 | 0.70 | CA12 (0.60) | KMT2AMEN1ALDH1A1HPGDLMNA | |
| SCHEMBL6673635 | 0.70 | HPGD (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL13938552 | 0.68 | KMT2A (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2021787 | 0.68 | TSHR (0.61) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4426558 | 0.68 | GABRP (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383733-B1 | PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2008-03-05 | — | — | EP | claimed |
| US-7091372-B2 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | PFIZER INC (US) | 2006-08-15 | — | — | US | claimed |
| EP-1383733-A2 | PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2004-01-28 | — | — | EP | claimed |
| US-20030060624-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic componunds | PFIZER INC. | 2003-03-27 | — | — | US | claimed |
| WO-2002085843-A2 | PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-10-31 | — | — | WO | claimed |
| EP-1383733-B1 | PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2008-03-05 | — | — | EP | disclosed |
| US-7186870-B2 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | PFIZER INC (US) | 2007-03-06 | — | — | US | disclosed |
| US-7091372-B2 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | PFIZER INC (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060079707-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | PFIZER INC | 2006-04-13 | — | — | US | disclosed |
| EP-1383733-A2 | PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030060624-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic componunds | PFIZER INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2002085843-A2 | PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079707-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | CYP1B1, AZI2, CYP1A1 | GABRP 3498/4885GABRD 3865/4885GABRA1 2538/4885 |
| US-20030060624-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic componunds | INTS6, CYP1B1, CYP1A2 | GABRP 2734/4885GABRD 2481/4885GABRA1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.